PIII vs MD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

PIII

50.2
AI Score
VS
MD Wins

MD

51.8
AI Score

Investment Advisor Scores

PIII

50score
Recommendation
HOLD

MD

52score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PIII MD Winner
Net Income -147.95M 69.42M MD
Operating Income -270.30M 98.58M MD
ROE 95.3% 7.9% PIII
ROA -22.5% 3.3% MD
Total Assets 656.64M 2.13B MD
Cash 25.01M 288.88M MD
Debt/Equity -1.76 0.69 PIII
Current Ratio 0.24 1.32 MD

Relative Price Performance (Last 90 Days)

PIII 1M: -27.9% · 3M: -37.8% MD 1M: +1.0% · 3M: +10.8%

Current Technical Phase

PIII

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 35

RSI (14): 35.4 · Price: $8.43

MD

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 53

RSI (14): 53.2 · Price: $26.77

Fundamentals Snapshot

Metric PIII MD
Market Cap
Forward P/E -0.6 11.0
Trailing P/E 12.8
Revenue (TTM)
Revenue Growth 0.1% 0.0%
Gross Margin 0.0% 0.3%
Operating Margin 0.1% 0.1%
EPS -32.47 2.09
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MD is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.